Novel treatment modalities: New platelet preparations and subsititutes

British Journal of Haematology

Volumn 114, Issue 3, 2001, Pages 496-505

  Lee, David H ^a   Blajchman, Morris A ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Blood substitutes; Platelet function; Platelet haemostatic function; Platelet substitutes; Platelets

Indexed keywords

ADENOSINE; ALBUMIN; AMILORIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; CRYOPROTECTIVE AGENT; DIMETHYL SULFOXIDE; FIBRINOGEN; HLA ANTIGEN; LIPOSOME; MICROSPHERE; NITROPRUSSIDE SODIUM; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; THROMBOCYTE CONCENTRATE; THROMBOSOL; THROMBOSPHERES;

APHERESIS; BACTERIAL INFECTION; BLOOD; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; RISK FACTOR; SEROLOGY; TECHNIQUE; THROMBOCYTE RICH PLASMA; THROMBOCYTOPENIA; VIRUS INFECTION;

ANIMALS; BLOOD PLATELETS; BLOOD PRESERVATION; CELL MEMBRANE; COLD; CRYOPRESERVATION; FACTOR VIIA; FIBRINOGEN; HEMOSTASIS; HLA ANTIGENS; HUMANS; LYSOSOMES; MICROSPHERES; MODELS, ANIMAL; PLATELET MEMBRANE GLYCOPROTEINS; PLATELET TRANSFUSION; PLATELETPHERESIS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0034790918     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03004.x     Document Type: Review

References (98)

1. Passive participation of fixed platelets in aggregation facilitated by covalently bound fibrinogen
2. Platelet-platelet recognition during aggregation: Distinct mechanisms determined by the release reaction
3. Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia
4. In vitro evaluation of the haemostatic effectiveness of non viable platelet preparations: Studies with frozen-thawed, sonicated, or lyophilized platelets
5. Frozen platelets and platelet substitutes in transfusion medicine
6. Reconstitution of platelet proteins into phospholipid vesicles-functional proteoliposomes
7. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor
8. Bacterial contamination and proliferation during the storage of cellular blood products
9. Immunomodulatory effects of allogeneic blood transfusions: Clinical manifestations and mechanisms
10. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo haemostatic efficacy of platelets and platelet substitutes
11. Preclinical testing of lyophilized platelets as a product for transfusion medicine
12. Analysis of platelet factor 3 in platelet concentrates stored for transfusion
13. Vesiculation of platelets during in vitro aging
14. Haemostatic properties of human lyophilized platelets in a thrombocytopenic rabbit model and a simulated bleeding time device
15. Lyophilized platelets: Nearing clinical trials
16. Lyophilized platelets correct the bleeding time test in a canine model of cardiopulmonary bypass
17. Activation and adherence of lyophilized human platelets on canine vessel strips in the Baumgartner perfusion chamber
18. Biologic effects of leukocytes present in transfused cellular blood products
19. Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying, freezing, or lyophilization: New stable platelet preparations for von Willebrand assays
20. Thromboerythrocytes reduce prolonged ear bleeding time in thrombocytopenic guinea pigs
21. Infusible platelet membrane microvesicles: A potential transfusion substitute for platelets
22. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional
23. Psoralens as photoactive probes of nucleic acid structure and function: Organic chemistry, photochemistry, and biochemistry
24. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: Defective platelet-fibrinogen interaction in thrombasthenia
25. Thromboerythrocytes: In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions
26. Recovery of in vitro functional activity of platelet concentrates stored at 4 degrees C and treated with second-messenger effectors
27. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates
28. Cryopreservation of single-donor platelets with a reduced dimethyl sulfoxide concentration by the addition of second-messenger effectors: Enhanced retention of in vitro functional activity
29. Enhanced circulatory parameters of human platelets cryopreserved with second-messenger effectors: An in vivo study of 16 volunteer platelet donors
30. Relative hemostatic effectiveness of platelets stored at 4° and 22°C
31. A method for evaluating the haemostatic efficacy of various agents in thrombocytopenic rats and mice
32. Intracellular function in rehydrated lyophilized platelets
33. Comparative effectiveness of fresh and lyophilized platelets in controlling irradiation hemorrhage in the rat
34. Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: Studies under flow conditions
35. Infusible platelet membranes improve haemostasis in thrombocytopenic blood: Experimental studies under flow conditions
36. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate
37. Platelet membrane glycoprotein changes during the preparation and storage of platelet concentrates
38. A phase I study of safety and efficacy for infusible platelet membrane in patients
39. Characterization of von Willebrand factor binding to infusible platelet membranes
40. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment
41. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions
42. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light
43. Fresh, disintegrated platelets in radiation thrombocytopenia: Correction of prothrombin consumption without correction of bleeding
44. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia
45. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on haemostasis and blood loss after cardiopulmonary bypass
46. The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia
47. Reduction of blood loss by infusion of human platelets in a rabbit kidney injury model
48. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia
49. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits
50. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
51. Effects of the addition of second-messenger effectors to platelet concentrates separated from whole-blood donations and stored at 4 degrees C or -80 degrees C
52. Platelet membrane vesicles reduced microvascular bleeding times in thrombocytopenic rabbits
53. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII
54. Cryopreservation of human platelets using 6% dimethyl sulfoxide and storage at -80°C
55. Concepts about current storage conditions for the preparation and storage of platelets
56. Platelet storage for transfusion
57. Platelet preservation. Effect of temperature on maintenance of platelet viability - Deleterious effect of refrigerated storage
58. Platelet production in the old world-and the new
59. Normalization of the haemostatic plugs of dogs with hemophilia A (factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles
60. Adhesion of liposomes carrying a recombinant fragment of platelet glycoprotein Ib or anti-collagen antibody to collagen surface under flow conditions - Approach to platelet substitutes
61. Prevention and management of platelet transfusion refractoriness
62. The reduction of HLA class I expression on platelets: A potential approach in the management of HLA-alloimmunized refractory patients
63. Transfusion-associated graft-versus-host disease
64. The role of platelet microparticles in haemostasis
65. Platelet microvesicles adhere to subendothelium and promote adhesion of platelets
66. Platelet membrane glycoprotein IIb-IIIa complex incorporated into phospholipid vesicles
67. Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: A pilot study
68. Human biodistribution of an ultrasound contrast agent (Quantison) by radiolabelling and gamma scintigraphy
69. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa
70. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
71. Preservation of haemostatic and structural properties of rehydrated lyophilized platelets: Potential for long-term storage of dried platelets for transfusion
72. Rehydrated lyophilized platelets: A proposed mechanism contributing to the haemostatic action
73. A method for the quantitative assessment of platelet-induced clot retraction and clot strength in fresh and stored platelets
74. Quality assessment of platelet concentrates supplemented with second-messenger effectors
75. Glycoproteins IIb and IIIa and platelet thrombospondin in a liposome model of platelet aggregation
76. A liposome based platelet substitute, the plateletsome with haemostatic efficacy
77. Fibrinogen binding to rehydrated lyophilized platelet surface GPIIb-IIIa: Normal clot formation and tPA lysis
78. Frozen autologous platelet transfusion for patients with leukemia
79. Infusible platelet membrane for control of bleeding in thrombocytopenic patients
80. Rehydrated lyophilized platelets retain GPIb receptors capable of interacting with the A1 loop of von Willebrand factor
81. Platelet cryopreservation. In vitro aggregation studies
82. Reconstitution of liposomes bearing platelet receptors for human von Willebrand factor
83. Platelet refractoriness and alloimmunization
84. Preparation and storage of platelet concentrates II. Storage variables influencing platelet viability and function
85. Morphological changes associated with pH changes during storage of platelet concentrates in first-generation 3-day container
86. Platelet storage lesion: Formation of platelet fragments with platelet factor 3 activity
87. Oxygen consumption, platelet aggregation, and release reactions in platelets freeze-preserved with dimethysulfoxide
88. Use of platelet derivatives and platelet substitutes in the management of thrombocytopenic states
89. Membrane phase transition of intact human platelets: Correlation with cold-induced activation
90. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa
91. S-59 (HelinxJ) photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: Results of the EuroSPRITE phase 3 trial
92. Liquid cold storage of platelets: A revitalized possible alternative for limiting bacterial contamination of platelet products
93. Summary of a workshop on in vivo efficacy of transfused platelets components and platelet substitutes
94. Mechanism of shape change in chilled human platelets
95. The nature and significance of platelet products in human plasma
96. Control of the post-irradiation hemorrhagic state by platelet transfusions
97. A new haemostatic agent: Thrombospheres shorten the bleeding time in thrombocytopenic rabbits
98. A novel approach to correcting the bleeding associated with thrombocytopenia